Dysregulation of miRNAs in AL amyloidosis

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–596.
   PubMed Web of Science ®Google Scholar
• Grossman RE, Hensley GT. Bone lesions in primary amyloidosis. Am J Roentgenol Radium Ther Nucl Med 1967;101:872–875.
   Google Scholar
• Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström’s macroglobulinemia. Clin Immunol Immunopathol 1994;71:183–189.
   PubMedGoogle Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
   PubMed Web of Science ®Google Scholar
• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 2007;14:261–269.
   PubMed Web of Science ®Google Scholar
• Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290–298.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492–496.
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936–2938.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465–470.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351–1358.
   PubMed Web of Science ®Google Scholar
• Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al.; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114:1489–1497.
   PubMed Web of Science ®Google Scholar
• Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol 2007;137:503–512.
   PubMed Web of Science ®Google Scholar
• Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008;452:1–10.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005;353:1768–1771.
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human MicroRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999–3004.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857–866.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271–1277.
   PubMed Web of Science ®Google Scholar
• Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008;105:5166–5171.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting Bcl2. Proc Natl Acad Sci USA 2005;102:13944–13949.
   PubMed Web of Science ®Google Scholar
• Vigorito E, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S et al. MicroRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007;27:847–859.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/MicroRNA-155 for normal immune function. Science 2007;316:608–611.
   PubMed Web of Science ®Google Scholar
• Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y et al. Regulation of the germinal center response by MicroRNA-155. Science 2007;316:604–608.
   PubMed Web of Science ®Google Scholar
• Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. Real-time quantification of MicroRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A MicroRNA polycistron as a potential human oncogene. Nature 2005;435:828–833.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 MicroRNA family. Cell 2005;120:635–647.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834–838.
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885–12890.
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669–6680.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S et al. Identification of MicroRNA expression patterns and definition of a MicroRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20–e26.
   Web of Science ®Google Scholar
• Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008;68:1012–1021.
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S et al. Quantitative technologies establish a novel MicroRNA profile of chronic lymphocytic leukemia. Blood 2007;109:4944–4951.
   PubMed Web of Science ®Google Scholar
• Dong JT, Boyd JC, Frierson HF Jr. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 2001;49:166–171.
   PubMed Web of Science ®Google Scholar
• Hyytinen ER, Frierson HF Jr, Boyd JC, Chung LW, Dong JT. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999;25:108–114.
   PubMed Web of Science ®Google Scholar
• Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E et al. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003;36:99–106.
   PubMed Web of Science ®Google Scholar
• Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Dávila R, González-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427–436.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000;96:1505–1511.
   PubMed Web of Science ®Google Scholar
• Gutiérrez NC, García JL, Hernández JM, Lumbreras E, Castellanos M, Rasillo A et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004;104:2661–2666.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL et al.; Intergroupe Francophone du Myélome. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185–2191.
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Mazzullo H, Ross FM, Cheung KL, Gerrard G, Harewood L et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol 2002;117:427–435.
   Google Scholar
• Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009;94:380–386.
   PubMed Web of Science ®Google Scholar
• Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV et al. Deregulation of MicroRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629–637.
   PubMed Web of Science ®Google Scholar
• Corthals SL, Jongen-Lavrencic M, de Knegt Y, Peeters JK, Beverloo HB, Lokhorst HM et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010;34:677–681.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853–858.
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220–1235.
   PubMed Web of Science ®Google Scholar